Edmund J. Pezalla, MD, MPH
CEO, Enlightenment Bioconsult, LLC
Dr. Pezalla in a leading innovator in payer strategy for pharmaceutical and device manufacturers. He focuses on unlocking the value of new products by developing industry-leading approaches to incorporating payer requirements into development programs, technology assessment plans, and value frameworks. He works with a variety of policy and industry groups on cutting edge coverage policy, innovations in value-based payments, and adaptive regulatory and market entry pathways.
Dr. Pezalla is the former Vice President for Pharmaceutical Policy and Strategy in the Office of the Chief Medical Officer at Aetna. In this position Dr. Pezalla developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna’s framework for innovative contracts, and developed Aetna’s public policy positions on drug and device coverage.
Current activity
Dr. Pezalla is active as a payer expert on a number of policy working groups including the New Drug Development Paradigm Project at MIT. He has recently been named a Scholar-in-Residence at the Duke-Margolis Health Policy Center in Washington, DC where he is working on policy approaches to stimulating the development of new antimicrobials, evaluation of value frameworks, and other policy projects. Dr. Pezalla is a member of the Board of Directors of the Pharmacy Quality Alliance and the Connecticut Biosciences Innovation Fund. He is also a member of the Business Advisory Board of Naia Pharmaceuticals and the Scientific Advisory Board of Temple Therapeutics.
Education/training
Dr. Pezalla received his BS in Biophysics from Georgetown University College of Arts and Sciences, and his MD Cum Laude from Georgetown University School of Medicine. He holds a Masters in Public Health from the University of California at Berkeley and was a health services research fellow and doctoral student in health policy at the University of Michigan.
Publications
Dr. Pezalla has co-authored a number of papers on adaptive licensing and other drug development issues and was an invited expert contributing to the report on Accelerating Innovation in Drug Development from the President’s Council of Advisors on Science and Technology.
BIBLIOGRAPHY
CEO, Enlightenment Bioconsult, LLC
Dr. Pezalla in a leading innovator in payer strategy for pharmaceutical and device manufacturers. He focuses on unlocking the value of new products by developing industry-leading approaches to incorporating payer requirements into development programs, technology assessment plans, and value frameworks. He works with a variety of policy and industry groups on cutting edge coverage policy, innovations in value-based payments, and adaptive regulatory and market entry pathways.
Dr. Pezalla is the former Vice President for Pharmaceutical Policy and Strategy in the Office of the Chief Medical Officer at Aetna. In this position Dr. Pezalla developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna’s framework for innovative contracts, and developed Aetna’s public policy positions on drug and device coverage.
Current activity
Dr. Pezalla is active as a payer expert on a number of policy working groups including the New Drug Development Paradigm Project at MIT. He has recently been named a Scholar-in-Residence at the Duke-Margolis Health Policy Center in Washington, DC where he is working on policy approaches to stimulating the development of new antimicrobials, evaluation of value frameworks, and other policy projects. Dr. Pezalla is a member of the Board of Directors of the Pharmacy Quality Alliance and the Connecticut Biosciences Innovation Fund. He is also a member of the Business Advisory Board of Naia Pharmaceuticals and the Scientific Advisory Board of Temple Therapeutics.
Education/training
Dr. Pezalla received his BS in Biophysics from Georgetown University College of Arts and Sciences, and his MD Cum Laude from Georgetown University School of Medicine. He holds a Masters in Public Health from the University of California at Berkeley and was a health services research fellow and doctoral student in health policy at the University of Michigan.
Publications
Dr. Pezalla has co-authored a number of papers on adaptive licensing and other drug development issues and was an invited expert contributing to the report on Accelerating Innovation in Drug Development from the President’s Council of Advisors on Science and Technology.
BIBLIOGRAPHY
- Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval; H-G Eichler, K Oye, L G Baird, E Abadie, J Brown, C L Drum, J Ferguson, S Garner, P Honig, M Hukkelhoven, J C W Lim, R Lim, M M Lumpkin, G Neil, B O'Rourke, E Pezalla, D Shoda, V Seyfert-Margolis, E V Sigal, J Sobotka, D Tan, T F Unger and G Hirsch; Clin Pharmacol Ther 91: 426-437; advance online publication, February 15, 2012; doi:10.1038/clpt.2011.345 http://www.nature.com/clpt/journal/v91/n3/abs/clpt2011345a.html
- Propelling Innovation in Drug Discovery, Development, and Evaluation. President’s Council of Advisors on Science and Technology; September 25, 2012. http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fda-final.pdf
- A New Market Access Pathway for Repurposed Drugs. Pahud D, et al. Ewing Marion Kauffman Foundation. May 14, 2014. www.kauffman.org/what-we-do/research/2014/05/a-new-market-access-pathway-for-repuprosed-drugs
- Accelerated Access to Innovative Medicines for Patients in Need. L G Baird, R Banken, H-G Eichler, F B Kristensen, D K Lee, J C W Lim, R Lim, C Longson, E Pezalla, T Salmonson, D Samaha, S Tunis, J Woodcock and G Hirsch. Clinical Pharmacology & Therapeutics Drug Development volume 96, issue 5; pages 559–571, November 2014
- Understanding and Overcoming Barriers to Medication Adherence: A Review of Research Priorities. Seth A. Seabury, Charu N. Gupta, Tomas J. Philipson, Laura E. Henkhaus. J Manag Care Pharm. 2014;20(8):775-83; http://www.amcp.org/JMCP/2014/August/18381/1033.html
- From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Hans-Georg Eichler, Lynn G Baird, Richard Barker, Brigitte Bloechl-Daum, Finn Børlum-Kristensen, Jeffrey Brown, Raymond Chua, Susanna Del Signore, Ute Dugan, John Ferguson, Sarah Garner, Wim Goettsch, Jeremy Haigh, Peter Honig, Anton Hoos, Paul Huckle, Tatsuya Kondo, Yann Le Cam, Hubert Leufkens, Robyn Lim, Carole Longson, Murray Lumpkin, John Maraganore, Brian O'Rourke, Ken Oye, Edmund Pezalla, Francesco Pignatti, June Raine, Guido Rasi, Tomas Salmonson, Dima Samaha, Sebastian Schneeweiss, Paolo Daniele Siviero, Mark Skinner, J. Russell Teagarden, Toshiyoshi Tominaga, Mark R. Trusheim, Sean Tunis, Thomas F. Unger, Spiros Vamvakas and Gigi Hirsch; Clinical Pharmacology & Therapeutics, 12 DEC 2014 03:09AM EST | DOI: 10.1002/cpt.59
- The next frontier: Fostering innovation by improving health data access and utilization. Oye KA, Jain, G, Amador M, Arnout R, Brown JS, Crown W, Ferguson J, Pezalla E, Rassen JA, Selker HP, Trusheim M, Hirsch G. Clin Pharm & Ther Adv in Neurodegenerative Diseases and Dementia, vol 98, issue 5, pages 514-512, Nov 2015
- Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need. G Hirsch, M Trusheim, E Cobbs, M Bala, S Garner, D Hartman, K Isaacs, M Lumpkin, R Lim, K Oye, E Pezalla, P Saltonstall and H Selker; Clin Pharm & Ther, (100)6, Dec2016
- Payer view of personalized medicine. Pezalla EJ, American Journal of Health-System Pharmacy December 2016, 73 (23) 2007-2012; DOI: https://doi.org/10.2146/ajhp160038
- Secular trends in opioid prescribing in the USA. Pezalla E, Rosen D, Erensen JG, Haddox JD, Mayne TJ. J Pain Res 2017(10)1-5. Jan2017
John Fox, MD, MHA
Associate Chief Medical Officer, Priority Health
Dr. Fox is the associate chief medical officer for Priority Health, a provider-sponsored health plan with 780,000 members headquartered in Grand Rapids, Michigan. Dr. Fox is responsible for technology assessment and medical policy development, total cost of care management, and innovations. These include pay-for-value contracting, integrated specialty pharmacy management, behavioral health initiatives, surgical optimization initiatives, community-based palliative care, and oncology medical home programs.
Prior to joining Priority Health, Dr. Fox was the chief medical officer at Physicians Plus Insurance in Madison, Wisconsin. He has also worked for the Indian Health Service and with the Epidemic Intelligence Service at the Centers for Disease Control and Prevention in Atlanta. Dr. Fox received his medical degree from Johns Hopkins University School of Medicine and a master’s degree in health administration from the University of Wisconsin. He completed a pediatric internship and residency at the Johns Hopkins Hospital and a fellowship in chronic disease epidemiology at the Centers for Disease Control and Prevention.
Dr. Fox has published on the use of firearms in suicides, physiatrist-led multidisciplinary spine clinics, breast cancer mortality, asthma hospitalizations, hip fractures among the elderly, primary care and oncology medical home programs, and end-of-life care. He has also written and lectured on value-based benefit design, the impact of genomics and proteomics on future medical practice, clinical outcomes-based contracting, and shared decision making in reducing variations in surgery rates, and the role of behavioral economics on health decisions and outcomes.
He is married to Kristine and has three children. His two sons are Eagle Scouts and his daughter a Gold Award recipient. He is very committed to youth leadership development and is active in the Boy Scouts of America as a troop leader and president of the board. He continues to practice medicine in third world countries, including Honduras, and leads one to two trips there annually with his church. He helps keep nature nearby through the Land Conservancy of West Michigan where he serves as a work crew leader and on its board of directors. He’s a longtime volunteer with Habitat for Humanity and still has all ten fingers and toes.
Associate Chief Medical Officer, Priority Health
Dr. Fox is the associate chief medical officer for Priority Health, a provider-sponsored health plan with 780,000 members headquartered in Grand Rapids, Michigan. Dr. Fox is responsible for technology assessment and medical policy development, total cost of care management, and innovations. These include pay-for-value contracting, integrated specialty pharmacy management, behavioral health initiatives, surgical optimization initiatives, community-based palliative care, and oncology medical home programs.
Prior to joining Priority Health, Dr. Fox was the chief medical officer at Physicians Plus Insurance in Madison, Wisconsin. He has also worked for the Indian Health Service and with the Epidemic Intelligence Service at the Centers for Disease Control and Prevention in Atlanta. Dr. Fox received his medical degree from Johns Hopkins University School of Medicine and a master’s degree in health administration from the University of Wisconsin. He completed a pediatric internship and residency at the Johns Hopkins Hospital and a fellowship in chronic disease epidemiology at the Centers for Disease Control and Prevention.
Dr. Fox has published on the use of firearms in suicides, physiatrist-led multidisciplinary spine clinics, breast cancer mortality, asthma hospitalizations, hip fractures among the elderly, primary care and oncology medical home programs, and end-of-life care. He has also written and lectured on value-based benefit design, the impact of genomics and proteomics on future medical practice, clinical outcomes-based contracting, and shared decision making in reducing variations in surgery rates, and the role of behavioral economics on health decisions and outcomes.
He is married to Kristine and has three children. His two sons are Eagle Scouts and his daughter a Gold Award recipient. He is very committed to youth leadership development and is active in the Boy Scouts of America as a troop leader and president of the board. He continues to practice medicine in third world countries, including Honduras, and leads one to two trips there annually with his church. He helps keep nature nearby through the Land Conservancy of West Michigan where he serves as a work crew leader and on its board of directors. He’s a longtime volunteer with Habitat for Humanity and still has all ten fingers and toes.
Jeffrey D. Dunn, Pharm.D., M.B.A.
Vice President, Clinical Strategy and Programs and Industry Relations, MagellanRx
Jeffrey D. Dunn, Pharm.D., M.B.A., is Vice President, Clinical Strategy and Programs and Industry Relations at MagellanRx (MRx). Prior to the business merger of MRx and Veridicus Health (VRx), Jeff was the Senior Vice President / Chief Clinical Officer / Board Member at VRx. MRx is a full service PBM and VRx incorporates PBM functions, P&T/formulary management, Medication Therapy Management (MTM)/Integrated Care Management (ICM), and government functions for commercial and Medicare Part D employer groups and health plans.
At MRx/VRx, Jeff oversees clinical functions, is involved in formulary (commercial and Medicare) management and benefit design, manages drug rebates, etc. He manages the VRx P&T process and sits on the MRx VAC. He also helps set strategy, including specialty management, with an emphasis on aligning medical and pharmacy benefits, channel management, site of care management, and unique benefit designs. VRx provides services to over 300,000 commercial members and over 10,000 Medicare Part D members. MRx provides services to over a million commercial and Medicaid members, and over 75,000 Medicare Part D members.
Previously Jeff was the Formulary and Contract Manager/Pharmacy Director for SelectHealth. SelectHealth is part of the integrated Intermountain Healthcare system that is comprised of 25 hospitals, 150 physician clinics and surgery centers, and more than 1,000 employed community-based physicians. It provides medical and pharmacy benefits to over 700,000 commercial, Medicare, and Medicaid members.
Dr. Dunn earned his doctor of pharmacy degree from the University of Utah College of Pharmacy and his Master of Business Administration degree from the David Eccles School of Business at the University of Utah. What attracted Jeff to managed care were the same things that he still enjoys fifteen years after graduating from pharmacy school – the combination of clinical, financial, and operational aspects of health care; and the ability to find solutions that help populations improve outcomes and save money. Jeff has been able to save health plans, employer groups, and members (patients) millions of dollars, while improving health outcomes by helping develop integrated care management programs, a pharmacist-centric MTM program, specialty strategies, etc. Jeff also enjoys interacting and working with pharmacy residents and students – Jeff helped develop (and manage) the residency programs at SelectHealth and VRx. Jeff and his wife, Sarah Jane, have endowed scholarships at the University of Utah Colleges of Pharmacy and Social Work. The Dunn’s have four beautiful and talented daughters and currently live in Draper, UT.
Vice President, Clinical Strategy and Programs and Industry Relations, MagellanRx
Jeffrey D. Dunn, Pharm.D., M.B.A., is Vice President, Clinical Strategy and Programs and Industry Relations at MagellanRx (MRx). Prior to the business merger of MRx and Veridicus Health (VRx), Jeff was the Senior Vice President / Chief Clinical Officer / Board Member at VRx. MRx is a full service PBM and VRx incorporates PBM functions, P&T/formulary management, Medication Therapy Management (MTM)/Integrated Care Management (ICM), and government functions for commercial and Medicare Part D employer groups and health plans.
At MRx/VRx, Jeff oversees clinical functions, is involved in formulary (commercial and Medicare) management and benefit design, manages drug rebates, etc. He manages the VRx P&T process and sits on the MRx VAC. He also helps set strategy, including specialty management, with an emphasis on aligning medical and pharmacy benefits, channel management, site of care management, and unique benefit designs. VRx provides services to over 300,000 commercial members and over 10,000 Medicare Part D members. MRx provides services to over a million commercial and Medicaid members, and over 75,000 Medicare Part D members.
Previously Jeff was the Formulary and Contract Manager/Pharmacy Director for SelectHealth. SelectHealth is part of the integrated Intermountain Healthcare system that is comprised of 25 hospitals, 150 physician clinics and surgery centers, and more than 1,000 employed community-based physicians. It provides medical and pharmacy benefits to over 700,000 commercial, Medicare, and Medicaid members.
Dr. Dunn earned his doctor of pharmacy degree from the University of Utah College of Pharmacy and his Master of Business Administration degree from the David Eccles School of Business at the University of Utah. What attracted Jeff to managed care were the same things that he still enjoys fifteen years after graduating from pharmacy school – the combination of clinical, financial, and operational aspects of health care; and the ability to find solutions that help populations improve outcomes and save money. Jeff has been able to save health plans, employer groups, and members (patients) millions of dollars, while improving health outcomes by helping develop integrated care management programs, a pharmacist-centric MTM program, specialty strategies, etc. Jeff also enjoys interacting and working with pharmacy residents and students – Jeff helped develop (and manage) the residency programs at SelectHealth and VRx. Jeff and his wife, Sarah Jane, have endowed scholarships at the University of Utah Colleges of Pharmacy and Social Work. The Dunn’s have four beautiful and talented daughters and currently live in Draper, UT.
Thomas G. Barsanti MD
Team Leader at Sanofi Genzyme for the National Medical Managed Care Team
Dr. Thomas Barsanti is a medical executive and physician with extensive leadership experience in health policy, pharmaceuticals, quality, and managed care. He is currently the team leader at Sanofi Genzyme for the National Medical Managed Care Team. This team serves as the medical lead for all national payers in the United States. Tom joined Genzyme as a Director for Multiple Sclerosis, Medical Managed Care in March, 2012 and worked with Express Scripts, United HealthCare, Magellan Rx and Walgreens. Dr. Barsanti joined Sanofi as a Medical Director for National Medical Management in 2010. He was the medical lead for Aetna and Medco Health Solutions, and helped collaborate with external partners on Health Care Reform. Previously, Dr. Barsanti worked for Well Point Inc. directing national case management activities to improve the coordination and delivery of health services for high risk patients, and served as the chief medical consultant for Hill and Knowlton’s Washington DC health services division.
From 2001-2009 he was a Medical Director with Pfizer Inc. From 2003-2009, Dr. Barsanti was involved in health care policy, speaking, and working with external organizations on issues such as pay for performance, the medical home, HIT, importation and DTC advertising. Dr. Barsanti was also active in Medicare Part D, and worked with external organizations to help expand product access with CMS. From 2001-2003, Dr. Barsanti was a Medical Director for Pfizer National Accounts where he led and coordinated medical relations with national managed care and pharmacy benefit medical directors. Prior to joining Pfizer, Dr. Barsanti was a Medical Director with Aetna U.S. Healthcare and Blue Cross BlueShield where he directed quality, utilization management, and NCQA accreditation.
Dr. Barsanti is a board certified Emergency Physician and served as Vice-President of an emergency medicine practice for ten years. He also chaired quality management activities in a large integrated hospital system where he directed physicians, led JCAHO accreditation, and improved patient care. Dr. Barsanti received his MD from the Medical College of Virginia and his undergraduate degree from the University of Virginia.
Team Leader at Sanofi Genzyme for the National Medical Managed Care Team
Dr. Thomas Barsanti is a medical executive and physician with extensive leadership experience in health policy, pharmaceuticals, quality, and managed care. He is currently the team leader at Sanofi Genzyme for the National Medical Managed Care Team. This team serves as the medical lead for all national payers in the United States. Tom joined Genzyme as a Director for Multiple Sclerosis, Medical Managed Care in March, 2012 and worked with Express Scripts, United HealthCare, Magellan Rx and Walgreens. Dr. Barsanti joined Sanofi as a Medical Director for National Medical Management in 2010. He was the medical lead for Aetna and Medco Health Solutions, and helped collaborate with external partners on Health Care Reform. Previously, Dr. Barsanti worked for Well Point Inc. directing national case management activities to improve the coordination and delivery of health services for high risk patients, and served as the chief medical consultant for Hill and Knowlton’s Washington DC health services division.
From 2001-2009 he was a Medical Director with Pfizer Inc. From 2003-2009, Dr. Barsanti was involved in health care policy, speaking, and working with external organizations on issues such as pay for performance, the medical home, HIT, importation and DTC advertising. Dr. Barsanti was also active in Medicare Part D, and worked with external organizations to help expand product access with CMS. From 2001-2003, Dr. Barsanti was a Medical Director for Pfizer National Accounts where he led and coordinated medical relations with national managed care and pharmacy benefit medical directors. Prior to joining Pfizer, Dr. Barsanti was a Medical Director with Aetna U.S. Healthcare and Blue Cross BlueShield where he directed quality, utilization management, and NCQA accreditation.
Dr. Barsanti is a board certified Emergency Physician and served as Vice-President of an emergency medicine practice for ten years. He also chaired quality management activities in a large integrated hospital system where he directed physicians, led JCAHO accreditation, and improved patient care. Dr. Barsanti received his MD from the Medical College of Virginia and his undergraduate degree from the University of Virginia.
Hemal Shah, PharmD
Principal/Owner of Value Matters, LLC
Hemal Shah, PharmD, is Principal/Owner of Value Matters, LLC and has over 20 years of experience in health economics & outcomes research, pricing, market access, value demonstration and health policy. She currently HEOR & market access strategic consulting services for clients in the life science industry. Hemal has worked with leading pharmaceutical and biotechnology companies, health care delivery organizations, and industry groups. Prior to establishing her consulting business in 2014, Hemal was Senior Vice President, Medical Affairs, Healthcare Quality, Policy and Outcomes at Optimer Pharmaceuticals (acquired by Cubist pharmaceuticals) from January 2011 to December 2013 where she was responsible for overall leadership, strategy, vision and execution of the Medical Affairs, Health Economics & Outcomes Research, Healthcare Quality/Public Policy and New Products/Life Cycle Planning teams and managed the establishment/expansion of field-based MSL and HEOR teams.
Principal/Owner of Value Matters, LLC
Hemal Shah, PharmD, is Principal/Owner of Value Matters, LLC and has over 20 years of experience in health economics & outcomes research, pricing, market access, value demonstration and health policy. She currently HEOR & market access strategic consulting services for clients in the life science industry. Hemal has worked with leading pharmaceutical and biotechnology companies, health care delivery organizations, and industry groups. Prior to establishing her consulting business in 2014, Hemal was Senior Vice President, Medical Affairs, Healthcare Quality, Policy and Outcomes at Optimer Pharmaceuticals (acquired by Cubist pharmaceuticals) from January 2011 to December 2013 where she was responsible for overall leadership, strategy, vision and execution of the Medical Affairs, Health Economics & Outcomes Research, Healthcare Quality/Public Policy and New Products/Life Cycle Planning teams and managed the establishment/expansion of field-based MSL and HEOR teams.
Maria Lopes, MD, MS
Chief Medical Officer, MagellanRx
Dr. Lopes has been in the managed care industry for over 19 years. She is currently the Chief Medical Officer of MagellanRx, former Chief Medical Officer of GHI/EmblemHealth, Chief Medical Director of Horizon BCBS NJ and CMO with AMCHealth.
In her role at MagellanRx, she oversees clinical program development and implementation, patient outreach and clinical assessment, pathway development and strategic solutions in: Oncology, RA, MS, IVIG, HAE, HIV, HepC, Neurotoxins, Gaucher’s, Hemophilia and PAH. She works closely with over 40 health plans to bring customized and innovative programs that add quantifiable clinical and economic value.
Dr. Lopes has extensive experience in Disease and Case Management, Employee Health and Wellness, and Quality initiatives to improve HEDIS/Medicare STAR performance. She has been responsible for Medical Policy Development and Implementation, Correct Coding initiatives, Fraud and Abuse, Physician Profiling and the development of a Medical Home Pilot project in NY. She has overseen Medical and Pharmacy Utilization in a network and a staff model. She has worked closely with Geisinger Health Systems on innovative strategies in e-Health, data analytics and HIT to improve patient engagement, care coordination and align incentives as part of Geisinger's Proven Health Navigator (Advanced Medical Home).
Dr. Lopes is an Obstetrician and Gynecologist. She has a BA in Biochemistry from Wesleyan University, received her Medical Degree from the University of Connecticut and has a Masters Degree in Administrative Medicine from the University of Wisconsin.
Chief Medical Officer, MagellanRx
Dr. Lopes has been in the managed care industry for over 19 years. She is currently the Chief Medical Officer of MagellanRx, former Chief Medical Officer of GHI/EmblemHealth, Chief Medical Director of Horizon BCBS NJ and CMO with AMCHealth.
In her role at MagellanRx, she oversees clinical program development and implementation, patient outreach and clinical assessment, pathway development and strategic solutions in: Oncology, RA, MS, IVIG, HAE, HIV, HepC, Neurotoxins, Gaucher’s, Hemophilia and PAH. She works closely with over 40 health plans to bring customized and innovative programs that add quantifiable clinical and economic value.
Dr. Lopes has extensive experience in Disease and Case Management, Employee Health and Wellness, and Quality initiatives to improve HEDIS/Medicare STAR performance. She has been responsible for Medical Policy Development and Implementation, Correct Coding initiatives, Fraud and Abuse, Physician Profiling and the development of a Medical Home Pilot project in NY. She has overseen Medical and Pharmacy Utilization in a network and a staff model. She has worked closely with Geisinger Health Systems on innovative strategies in e-Health, data analytics and HIT to improve patient engagement, care coordination and align incentives as part of Geisinger's Proven Health Navigator (Advanced Medical Home).
Dr. Lopes is an Obstetrician and Gynecologist. She has a BA in Biochemistry from Wesleyan University, received her Medical Degree from the University of Connecticut and has a Masters Degree in Administrative Medicine from the University of Wisconsin.
Richard Howard Williams, RPh
Account Management, Eli Lilly
Richard has spent more than 25 years in sales, sales leadership and account management at Eli Lilly & Company. His experience includes Retail, Hospital, Long Term Care, Medicaid, Medicare, National Accounts, and Integrated Delivery Systems. As a district sales manager, Richard and his teams have received numerous awards for launching new products. As a National Account Manager, Richard worked with companies like Coventry Healthcare, Member Health, Cigna, and Aetna to secure access for Lilly products. Richard currently has responsibility for the state of Tennessee. This includes payers, Tenncare, ACOs, IDN’s, and pharmacy initiatives. During his career at Lilly, Richard has launched more than 15 products in therapeutic areas including Neuroscience, Diabetes, Osteoporosis, Men’s Health and Oncology.
Richard graduated from the Ole Miss School of Pharmacy. Prior to joining Lilly he worked as a Retail and Hospital pharmacist and was the owner of Williams Drug Store. Richard currently serves as Chairman of the Board for Hope Smiles, and is an advisor and mentor to the Oak Project. He has a passion for coaching and mentoring millennials. He and his wife currently live outside Nashville TN.
Account Management, Eli Lilly
Richard has spent more than 25 years in sales, sales leadership and account management at Eli Lilly & Company. His experience includes Retail, Hospital, Long Term Care, Medicaid, Medicare, National Accounts, and Integrated Delivery Systems. As a district sales manager, Richard and his teams have received numerous awards for launching new products. As a National Account Manager, Richard worked with companies like Coventry Healthcare, Member Health, Cigna, and Aetna to secure access for Lilly products. Richard currently has responsibility for the state of Tennessee. This includes payers, Tenncare, ACOs, IDN’s, and pharmacy initiatives. During his career at Lilly, Richard has launched more than 15 products in therapeutic areas including Neuroscience, Diabetes, Osteoporosis, Men’s Health and Oncology.
Richard graduated from the Ole Miss School of Pharmacy. Prior to joining Lilly he worked as a Retail and Hospital pharmacist and was the owner of Williams Drug Store. Richard currently serves as Chairman of the Board for Hope Smiles, and is an advisor and mentor to the Oak Project. He has a passion for coaching and mentoring millennials. He and his wife currently live outside Nashville TN.